Core Viewpoint - The announcement highlights a strategic collaboration between Innovent Biologics and Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, marking their seventh partnership and reinforcing a long-term productive relationship [1] Group 1: Strategic Collaboration - Innovent Biologics, along with its subsidiaries, has entered into a strategic partnership with Eli Lilly to enhance the global R&D of innovative drugs in the oncology and immunology sectors [1] - This agreement represents the seventh collaboration between the two companies, indicating a deepening of their long-term and effective partnership [1] - The unique collaboration framework is expected to create a new model for cooperation, accelerating the global development process of the company's innovative R&D pipeline [1]
信达生物与礼来制药达成全球战略合作 推进肿瘤及免疫领域的新药开发